Vertex Pharmaceuticals (Australia)

FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain

FDA · moderate-to-severe acute pain · 7 min

The FDA approved Vertex Pharmaceuticals’ Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults. The decision creates a new non-opioid catalyst to track for BD teams, investors, and analysts.

FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx

FDA · moderate-to-severe acute pain · 8 min

The FDA approved Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults, including postoperative pain. The decision gives Vertex the first non-opioid analgesic in this setting and creates a new catalyst set for BD teams, investors, and analysts.

Vertex launches Journavx after FDA approval for acute pain

FDA · oncology · 9 min

Vertex’s Journavx (suzetrigine) became the first FDA-approved non-opioid analgesic for moderate to severe acute pain on January 30, 2025. This plan frames the catalyst, label, and upcoming clinical milestones for BD teams, investors, and analysts.

Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

FDA · IgA Nephropathy · 4 min

Vertex Pharmaceuticals announced that the FDA has accepted its Biologics License Application for accelerated approval of povetacicept in IgA nephropathy, with a PDUFA target date of November 30, 2026. The filing is supported by positive week 36 interim analysis data.